Effectiveness of Methotrexate and Apremilast in the Management of Moderate to Severe Plaque Psoriasis: A Comparative Study
Authors/Creators
- 1. Assistant Professor, Department of DVL, Ayaan Institute of Medical Sciences, Moinabad, Hyderabad, Telangana, India
Description
Introduction: Psoriasis chronic inflammatory skin disorder typically characterized by erythematous papules and plaques. Methotrexate acts by inhibiting dihydrofolic reductase enzyme and apremilast is an oral phosphodiesterase-4 inhibitor, which are effective in the management of moderate to severe psoriasis. The current study was aimed to evaluate the effectiveness of methotrexate and apremilast in treating moderate to severe plaque psoriasis. Material and methods: A total of 52 participants of both genders with moderate to severe plaque psoriasis attending outpatient department aged between 18 to 60 years were included. Participants were randomly divided in to group 1 (n=26) medicated with 7.5 mg Methotrexate per week and group 2 (n=26) medicated with Apremilast with a started dose of 10 mg and titrated to a maximum dose of 30 mg two time in a day. The participants were assessed for treatment response and adverse effects for a period of 4 months. The severity of psoriasis was assessed by psoriasis are severity index (PASI). Results: The mean age of onset was 36.7 years in group 1 and 35.28 years in group 2. 73.1% were suffering with <2 years and 46.2% were suffering with >2 years. SCALP was commonly affected part (80.8% each), followed by nails (61.5% & 57.7%), palm and sole (26.9% & 30.76%). 84.61% and 80.76% patients were achieved PASI75 in group 1 and 2 respectively. Headache is common adverse event followed by nausea, vomiting and lower abdomen pain. 3.84% of patients. Conclusion: Methotrexate and Apremilast did not show significant difference in achieving PASI75 at the end of 4th month of treatment and are equally efficacious in the management of moderate to severe grade psoriasis.
Abstract (English)
Introduction: Psoriasis chronic inflammatory skin disorder typically characterized by erythematous papules and plaques. Methotrexate acts by inhibiting dihydrofolic reductase enzyme and apremilast is an oral phosphodiesterase-4 inhibitor, which are effective in the management of moderate to severe psoriasis. The current study was aimed to evaluate the effectiveness of methotrexate and apremilast in treating moderate to severe plaque psoriasis. Material and methods: A total of 52 participants of both genders with moderate to severe plaque psoriasis attending outpatient department aged between 18 to 60 years were included. Participants were randomly divided in to group 1 (n=26) medicated with 7.5 mg Methotrexate per week and group 2 (n=26) medicated with Apremilast with a started dose of 10 mg and titrated to a maximum dose of 30 mg two time in a day. The participants were assessed for treatment response and adverse effects for a period of 4 months. The severity of psoriasis was assessed by psoriasis are severity index (PASI). Results: The mean age of onset was 36.7 years in group 1 and 35.28 years in group 2. 73.1% were suffering with <2 years and 46.2% were suffering with >2 years. SCALP was commonly affected part (80.8% each), followed by nails (61.5% & 57.7%), palm and sole (26.9% & 30.76%). 84.61% and 80.76% patients were achieved PASI75 in group 1 and 2 respectively. Headache is common adverse event followed by nausea, vomiting and lower abdomen pain. 3.84% of patients. Conclusion: Methotrexate and Apremilast did not show significant difference in achieving PASI75 at the end of 4th month of treatment and are equally efficacious in the management of moderate to severe grade psoriasis.
Files
IJPCR,Vol15,Issue6,Article251.pdf
Files
(418.7 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:8193687afdfcb599fc198a86476343cb
|
418.7 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-05-30
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue6,Article251.pdf
- Development Status
- Active
References
- 1. Raharja A, Mahil SK, Barker JN: Psoriasis: a brief overview. Clin Med (Lond). 2021; 21:170-3. 2. Thappa DM, Munisamy M: Research on psoriasis in India: where do we stand? Indian J Med Res. 2017; 146: 147-9. 3. Gao JC, Wu AG, Contento MN, Maher JM, Cline A: Apremilast in the treatment of plaque psoriasis: differential use in psoriasis. Clin Cosmet Investig Dermatol. 2022; 15: 395-402. 4. Dogra S, Mahajan R: Psoriasis: epidemiology, clinical features, comorbidities, and clinical scoring. Indian Dermatol Online J. 2016; 7:471-80. 5. Puig L. Incremental cost per responder (PASI-75, PASI-90 and PASI-100) based on a network meta-analysis of biologic therapies for psoriasis: Spain 2018. Actas Dermosifiliogr. 2019; 110:517–8. 6. Cutolo M, Myerson GE, Fleischmann RM, Lioté F, Díaz-González F, Van den Bosch F, et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: Results of the PALACE 2 trial. J Rheumatol. 2016; 43:1724–34. 7. Warren RB, Chalmers RJ, Griffiths CE, Menter A: Methotrexate for psoriasis in the era of biological therapy. Clin Exp Dermatol. 2008; 33:551-4. 8. Yelamos O, Puig L. Systemic methotrexate for the treatment of psoriasis. Expert Rev Clin Immunol 2015; 11:553-63. 9. Orasan MS, Roman II, Coneac A. Evaluation of Psoriasis Patients. Tailored Treat Psoriatic Patients. Intech Open. 2018. Available at https://www.intechopen.com/onlinefirst/evaluationof psoriasis-patients 10. James WD, Berger TG, Elson DM. Andrews' diseases of the skin Clinical Dermatology, 11th ed, Elsevier Inc, 2011:190-8. 11. Rosie TN, Khan AL, Khan MSl, Yazdi QS, Karim ATMR. Efficacy and Safety of Apremilast versus Methotrexate in the Treatment of Chronic Plaque Psoriasis. JAFMC Bangladesh. 2020;16(1):39-41. 12. Lubna Khondker. Efficacy and safety of Apremilast in the treatment of patients with moderate to severe plaque psoriasis. The Gulf Journal of Dermatology and Venereology. 2020;27(2):6-15. 13. Kaplan, David et al. "Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use." Journal of comparative effectiveness research. 2022;11(8):575-582. 14. Hassanandani T, Panda M, Jena AK, Raj C. Methotrexate monotherapy versus methotrexate and apremilast combination therapy in the treatment of palmoplantar psoriasis: A prospective, randomised, assessorblinded, comparative study. Indian journal of dermatology, venereology and leprology. 2023; 89(2): 213-220. 15. Panda Gautam, Jyoti PS, Mohanty P, Trupti RS. Apremilast orMethotrexate: The Arrows in the Quiver for Psoriasis. Cureus 2023; 15(5): e38802. 16. Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson JM, Chen R, Goncalves J, Levi E, Callis Duffin K.Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study. J Drugs Dermatol. 2017; 16 (8):801-808. 17. Ighani, Arvin et al. "Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study." Journal of cutaneous medicine and surgery. 22,3 (2018): 290-296. 18. Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz, Ferrandiz C et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). The British journal of dermatology. 2015; 173(6):1387-99. 19. Spencer Riley K, Kareem G Elhage , Joy Q Jin , Mitchell S Davis et al. Apremilast in Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Meta-analysis. Dermatology and therapy. 2023; 13(2): 437-451. 20. Kt S, Thakur V, Narang T, Dogra S, Handa S. Comparison of the efficacy and safety of apremilast and methotrexate in patients with palmoplantar psoriasis: a randomized controlled trial. Am J Clin Dermatol. 2021;22(3):415–23. 21. Samanta, Joydeep et al. Comparison between methotrexate and apremilast in Psoriatic Arthritis-a single blind randomized controlled trial (APREMEPs A study). Rheumatology international. 2023; 43(5): 841-848.